Navigation Links
ArunA Biomedical Names Harold Ingalls to its Board of Directors

ATHENS, Ga., Sept. 9 /PRNewswire/ -- ArunA Biomedical, Inc., the first company to commercialize human embryonic stem cell derived products and services, announced today the appointment of former Serologicals Corporation CFO, Harold "Bud" Ingalls, to its Board of Directors.

(Logo: )

Mr. Ingalls brings over 40 years of financial leadership, including nearly 20 years of experience as a chief financial officer to ArunA's Board. Prior to his current role as CFO of Premier Exhibitions, Mr. Ingalls served as Vice President and Chief Financial Officer at CardioMEMS, where he played a key role in the organization's transformation. During his tenure at CardioMEMS, Mr. Ingalls led the completion of two private financing rounds totaling over $45 million with venture capitalists and strategic investors. From 2001 to 2006, he held the position of Vice President of Finance and Chief Financial Officer of Serologicals Corporation. Under Mr. Ingalls' leadership, Serologicals' enterprise value increased by nearly $1.0 billion, as the result of strong organic growth, successful acquisitions and stringent cost control. Prior to his work with Serologicals, Mr. Ingalls was employed as President and Chief Financial Officer of LaRoche Industries, Inc. Mr. Ingalls is a member of the American Institute of Certified Public Accountants and received a BBA degree in Accounting from the University of Wisconsin.

"We are pleased to welcome Bud to the ArunA Board. His domain knowledge and impressive combination of strategic and financial expertise in the life sciences industry will be a tremendous asset to ArunA Biomedical as we move forward in our next phase of growth," said ArunA President and CEO, William T. Sharp.

About ArunA Biomedical

Located in Athens, Georgia, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human stem cell research for use in drug discovery and basic research. ArunA is the first company to commercialize products derived from human embryonic stem cells and sees its proprietary technology as a catalyst leading to the discovery of novel therapeutic compounds, tests for neurotoxicity and breakthroughs in understanding human development and diseases.

For more information, visit:

SOURCE ArunA Biomedical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Therapeutic DNA Vaccine Company Inovio Biomedical Reports Second Quarter 2008 Financial Results
2. Response Biomedical Corporation Announces Strategic Partnership with Roche Diagnostics To Commercialize Cardiovascular Tests
3. Creator of PubMed Central biomedical research database recognized for outstanding citizen service
4. Singapore Reinforces Position as a Global Site for Pharma & Biotech; Biomedical Manufacturing Output Quadruples to Reach US$17 Billion
5. BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the Barbed OSStaple(TM) (BOSS) Nitinol Implant
6. Twenty of Americas Most Promising Scientists Selected as 2008 Pew Scholars in the Biomedical Sciences
7. The Foundation for Biomedical Research (FBR) Releases Feature DVD Majestic for World Premiere
8. BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the OSSAnchor(TM) Grip Nitinol Soft Tissue Anchor
9. Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
10. The 2008 AMIA Spring Congress to Showcase Best Practices and Innovations in Biomedical and Health Informatics Research and Education
11. Marc Feldmann and Sir Ravinder Maini win Dr. Paul Janssen Award for Biomedical Research
Post Your Comments:
(Date:11/25/2015)... ... 2015 , ... The McHenry County law firm of Botto Gilbert Lancaster, ... Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the claimant ... (2d) 130884WC. , According to court documents, Adcock testified that on May 10, 2010 ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, AZ) - Today, ... specializing in both surgical and non-surgical treatments, announced the expansion of his private ... Plastic Surgery. , Highly trained and nationally recognized for his natural approach, ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical ... Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of its product ... intensive care units (totaling 30 beds) from May 2014 through October 2015 at a ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... provide scholarships for people struggling with eating disorders as a result of the ... second annual event, held at Fox Run Golf Club in Eureka, will help ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... that it has undertaken significant expansion of its current state of the art ... part of PharmaTech’s strategy to increase its manufacturing capacity as well as to ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 25, 2015  Amgen (NASDAQ: AMGN ) today ... with the United States (U.S.) ... biosimilar candidate to Humira ® (adalimumab). Amgen believes ... to the FDA and represents Amgen,s first BLA submission ... Harper , M.D., executive vice president of Research and ...
(Date:11/25/2015)... , Nov. 25, 2015 AAIPharma Services ... investment of at least $15.8  Million to expand ... Wilmington, NC . The expansion will provide ... meet the growing demands of the pharmaceutical and ... site expansion will provide up to 40,000 square ...
(Date:11/25/2015)...  Henry Schein, Inc., the world,s largest provider of ... and animal health practitioners, will unveil at the Greater ... ConnectDental® Pavilion , which brings together for the first ... to help any practice or laboratory enter the digital ... schedule of experts appearing at the Pavilion. --> ...
Breaking Medicine Technology: